Reuters logo
Lundbeck says study shows efficiency in Parkinson's drug
March 20, 2013 / 11:28 AM / 5 years ago

Lundbeck says study shows efficiency in Parkinson's drug

COPENHAGEN, March 20 (Reuters) - Danish pharmaceutical group Lundbeck said on Wednesday a clinical study had concluded its Parkinson’s treatment Azilect was efficient and tolerable as an add-on treatment compared with a placebo.

The study was conducted at 50 research sites in the United States, Lundbeck said in a joint statement with Israeli partner Teva Pharmaceutical Industries Ltd.

Reporting by Copenhagen Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below